Please email the editors at 'theniche at nature.com' to propose new posts.

« January 2009 | Main | March 2009 »

Archive by date: February 2009

Bookmark in Connotea

Stem-cell funding ban: what's Obama waiting for?

Meredith Wadman's article on NatureNews explores why Obama has not yet lifted the ban on federal funds for human embryonic stem cell research. Some say that he's preoccupied with the economic crisis; others that the Administration feels simply reversing the executive order isn't enough, and so new legislation is required. One worry: the Dickey-Wicker amendment, which predates the Bush funding ban, might be interpreted to prohibit funds for the research. This legislation, which has been renewed yearly ever since its enactment in 1995, prohibits the use of federal funds that create or destroy embryos. Many legal scholars doubt it would apply to research on cells after the embryos have been derived, but the concern is real.

For more reading, see my news round-up last week.
Also see advice that advocacy groups offered Obama on stem cell research. The group American Progress, in particular, offered strong advice to have hES research supported by Congressional legislation.

Finally, see our comparison between how hES research policy has developed in Germany, the United Kingdom, and the United States.

Bookmark in Connotea

FDA puts plan for a neural stem cell trial on hold

The FDA has ordered a halt to NeuralStem's plans for a neural stem cell trial in Lou Gehrig’s disease (amyotrophic lateral sclerosis). (See the company’s press release as well as a link to its December announcement that it had filed an IND) NeuralStem says that the FDA’s concerns and recommendations can be readily addressed.

Clinical holds are not unusual, especially for novel therapies. In fact, Geron received a clinical hold in May 2008 before ultimately getting permission to proceed in January 2009. In July, Geron plans to use cells derived from embryonic stem cells to treat spinal cord injury. (See the Nature story) I covered the hold in a blog posting, which also contains links to a summary of the FDA advisory meeting on how to evaluate safety risks for cells derived from embryonic stem cells. Hopes were high at that meeting. So was anxiety.

The FDA’s decision to delay NeuralStem’s trial comes just days after descriptions of an unregulated transplant of fetal neural stem cells that developed into tumours in a patient’s brain and spinal cord. The patient, who has a neurodegenerative disease, was taken by his parents for an unregulated stem cell therapy in Moscow. Doctors in Israel found the growths after the patient complained of headaches.
See the Nature News story. Researchers and physicians I spoke to while reporting the story were outraged that the procedure had occurred. They said that there was no evidence that it could help, and that no rigorous safety studies or even cell characterization had been completed. They took pains to distance the procedure from mainstream clinical research, but at the same time emphasized that all novel treatments carry risk.
(See our expert commentary on unregulated stem cell treatments, which has links to guidelines from the International Society for Stem Cell Research)

Stem-cell treatments involving bone marrow are well established, and though evidence of benefit for mesenchymal stem cells is still preliminary (See Nature Reports story), they do not seem to cause harm. Stem-cell treatments for neurodegenerative diseases are still very much at the beginning. Even with rigorous studies, the field will likely have more questions than clarity for some time to come.

Bookmark in Connotea

Investors ♥ stem cells

Enthusiasm was more apparent than scepticism at the 4th Annual Stem Cell Summit, organized by investor, analyst and stem cell fan Robin Young, head of RRY Publications. This conference brought together a motley collection of companies, both well-known and obscure, and each was given ten minutes to tout themselves to potential investors and partners. Business models included cell banking, services, therapies, medical devices and tools; even the smallest companies were often relying on multiple business models.

Several attendees were also planning on going to the Stem Cell Partnering Series, a separate conference put on in cooperation with the International Society for Stem Cell Research, which is going on at the University of California, San Diego on 26 and 27 February. I unfortunately won’t be able to attend that one, but you can get more information here.

In New York on Tuesday, Young himself acknowledged the dizzying diversity of companies represented, speculating whether the term 'stem cell' had become an inadequate term for business models applying to many things. Companies at the conference were funded by their own sales revenues, private investors, government grants, venture capital and big pharma partners. Several of the more established companies were recently discussed in an upbeat article in Crain’s Cleveland Business.

Continue reading "Investors ♥ stem cells" »

Bookmark in Connotea

Positive results from a heart stem-cell trial, and plans for more

The mesenchymal stem-cell company Osiris has announced positive results of its two-year 53-patient trial in heart disease. According to the press release,
patients receiving Osiris’s product Prochymmal had fewer arrhythmias. About 12% of treated patients had arrhythmias compared to 47% of those receiving a placebo treatment. (Even though the press release reports percents, remember that there are less than 100 patients in the trial). Osiris also reported no immune-related side effects. That’s significant, because unlike other adult stem cell therapies which return a patient’s own cells back into the patient, Osiris uses cells collected from the bone marrow of healthy donors. (But see a cautionary report from a mouse study)

A recent article in Nature Biotechnology (subscription required) describes the $1.38 billion dollar deal ($130 million upfront) that Genzyme made with Osiris for its mesenchymal stem cell technology. These cells are thought to secrete factors that help the heart heal itself.

Osiris is planning a 220-patient phase II trial for patients that have experienced a single heart attack. According to the company, “efficacy endpoints determined from cardiac MRI include end systolic volume, LVEF and the ability of Prochymal to preserve functional heart tissue, or limit scar formation following a heart attack. In addition, functional and quality of life assessments will be performed.”

This is one of several approaches to using stem cells in the heart. We covered these in a feature last year:
Stem cells for the heart, a new wave of clinical trials Also see a review by Andre Terzic on how stem cells can be used in regenerative medicine that just came out this month.

Just last week, researchers announced plans to launch a clinical trial testing another approach. That will biopsy heart tissue from heart attack patients, extract stem cells from it and reinject the stem cells into the scarred areas of the heart. This was written about in BusinessFirst of Louisville, Kentucky.

Q&A with Christine Mummery: Regenerating the heart

Bookmark in Connotea

So many papers, so little time

There are more cool papers published than I can keep track of. In an effort to clear my head, I’ve mentioned and linked to just a few, going back to January. Please point out your favourites that I’ve left out.

What makes HSCs stop and go? (and can we watch?)
The list of exactly what genes haematopoietic stem cells require is constantly debated, revised and re-revised. Professor Iconoclast (aka Sean Morrison of University of Michigan in Ann Arbor) says that HSCs do just fine without N-cadherin. Meanwhile, another paper says HSCs do seem to need at least one of the pair Lyl1 and Scl, though each is singly dispensable. And E2A proteins are necessary for maintenance. Two more papers show that p53 is important for stem cell quiescence and that it can be monitored in more ways than one might think.

(Cancer) stem cells are survivors
A new Nature paper shows how breast cancer stem cells and their healthy counterparts protect their DNA from radiation. I wrote about how that paper came to be. See also a recent review on how cancer stem cells can be targeted.Jim Till (yes, that’s the same Till of Till and McCulloch) has listed articles on Clarke’s and Reya’s and others’ work on his cancer stem cell blog.

More mouse cures from iPS

Continue reading "So many papers, so little time" »

Bookmark in Connotea

Jerry Yang, cloning pioneer and stem-cell advocate, dies

I’ve just read with sadness that Xiangzhong “Jerry” Yang of the University of Connecticut has died of cancer. Here are articles from the Associated Press and the Contra Costa Times. The most extensive piece is this excellent one in the Hartford Courant.

Jerry Yang was one of the first scientists that I spoke with after Nature Reports was launched just over a year and a half ago. His enthusiasm and advice were important in organizing the meeting where the leaders of what was to become the Stem Cell Network of the Asia-Pacific Region (SNAP) first publicly proposed its formation. I remember his patience as I struggled to understand some distinctions that are obvious to me now, and how valuable his review on therapeutic reprogramming of cloned embryos was to me as I wrote my first features for Nature Reports. I remember how passionately he worked to convince governments in China and Connecticut to support stem cell research.

His family, friends and colleagues have my warmest sympathies. The stem cell community will miss him.

Bookmark in Connotea

News round-up: Obama and the stem-cell ban

President Obama has promised Democrats that the ban on the federal funding for human embryonic stem cell research will be lifted. See this blog post from the Washington Post. The first paragraph of this Washington Times article describes the context of one such promise, and then abandons further policy discussion to describe presidential air travel. Meanwhile, this more analytic piece in the Philadelphia Inquirer describes why Obama seems to prefer legislative action to allow embryonic stem cell research, and why scientists seem to prefer it too, as it would mean that subsequent presidents couldn’t re-impose the ban by fiat. More than a swift lifting of the funding ban, Obama seems to value implementing the economic stimulus package and coordinating with Congress.

Also on the ban-lifting topic,The Journal of New England Technology has a local round-up of stem cell scientists excited about the funding ban's banishment, noting that it’s not just academic grants that will soon be eligible for funding, but small business grants as well. The well-written article surveys several scientists in both academia and industry.

Continue reading "News round-up: Obama and the stem-cell ban" »

Bookmark in Connotea

How cancers resist treatment, and more

Here are a couple papers just out in Nature. One, from Mike Clarke of Stanford, shows how human breast cancers resist treatment. I talked to him about how the paper came to be. The other, from Tannishtha Reyes of Duke, finds an alternative pathway to attack resistant leukemia in mice.

How breast cancer resists treatment
Self-renewing blood and leukaemia cells need hedgehog

Also, this week, a lovely feature about how getting interoperability between computational biologists and stem cell biologists.

Plus, a way to make mesenchymal turn into bone via physical stimulus.
Nanotubes guide mesenchymal stem cells toward becoming bone

Bookmark in Connotea

Reprogramming with all but Oct4

There's a paper just out in Cell today moving researchers closer to reprogramming without adding oncogenes. Sure, it starts with a cell type that's not readily accessed in humans, but it does indicate that the cell type could matter. Also of interest should be a paper that was published in Cell last week, which compared where the four Yamanaka factors are binding in fully reprogrammed cells, partially reprogrammed cells, and fibroblasts. (See how the four factors reprogram)

Cells that behave like embryonic stem cells can be made from cultured skin, liver, and stomach cells. All techniques so far require the addition of at least two pluripotency genes, which renders the cells much less attractive for cell therapy and drug screening. Now, researchers led by Hans Schöler of the Max Planck Institute for Molecular Biomedicine in Münster, Germany show that cells can be reprogrammed to pluripotency using just one of the standard four genes.1 “With only one “switch,” the gene Oct4, we have turned adult somatic cells into stem cells that are very similar to embryonic stem cells,” he says.

Schöler’s team began not with fibroblasts, the cultured skin cells most frequently used to make so-called induced pluripotent stem cells (iPS cells), but with mouse neural stem cells, which naturally express three of the four standard transcription factors. They were able to induce pluripotency by adding the gene for the missing factor, Oct4. Oct4, which is officially called Pou5F1, is expressed in embryonic stem cells and germ cells, and has long been considered a key regulator of pluripotency. The team had previously been able to reprogram neural stem cells using two of the four factors. The trick to using just one was waiting longer for cells to reprogram. Reprogramming generally takes about three weeks, but Schöler and his colleagues cultured the Oct4 infected cells for four to five weeks. The resulting cells passed several tests of pluripotency, including germline transmission in chimeric mice. The reprogramming efficiency was similar to that of reprogramming mouse embryonic fibroblasts with all four factors, about 0.014%.

Practical implications may be a ways off. Unlike skin cells, brain cells cannot be obtained readily from a human biopsy. However, Schöler says these cells present a good model for reprogramming not only because they can be transformed readily but also because they can be grown easily in pure cultures, so researchers can be certain what type of cells are being reprogrammed.

“The study sets the basis to understand, at a mechanistic level, whether Oct4 alone, in the absence of other oncogenes, could be used to reprogram different adult stem cells,” says Juan Carlos Izpisua Belmonte of the Salk Institute in La Jolla, California, whose work has shown that cells from plucked human hair reprogram much more swiftly and efficiently than fibroblasts. If such an approach could be made to work with more easily obtained cell types, the therapeutic implications would be “extraordinary,” he says. In the meantime, understanding what cell types are most susceptible to reprogramming “will surely help at unveiling the nuts and bolts of the process.”

Other techniques will also be helpful. Schöler and other researchers and other researchers previously showed that fetal neural stem cells could be reprogrammed without requiring the insertion of the Oct4 gene, though doing so required insertion of the other pluripotency genes plus a small molecule that inhibits an enzyme known as G9a histone methyltransferase. However, Schöler says that since this molecule turns on many genes, it requires the addition of the other three factors to focus the “crucial action” of Oct4.

[[Author Affiliation]] Monya Baker is editor of Nature Reports Stem Cells

1. Kim, J.B. et al. Oct4-induced pluripotency in adult neural stem cells. Cell 136, 411–419 (2009)

Related articles

Easing out the viruses in induced pluripotency


Small molecules boost reprogramming rates


Integration-free iPS cells


Embryonic-like stem cells from a single human hair

Bookmark in Connotea

CIRM training grants approved, but awards uncertain in financial climate

The governing board for the California Institute of Regenerative Medicine announced that it had decided to award $58 million to 26 grants for training stem-cell scientists and lab technicians. Delivery of these funds will have to wait, however, because California is unable to sell bonds on the public market. CIRM board members are even discussing raising funds through the private bond market. (See the press release as well as the story from the San Diego Tribune and the San Francisco Chronicle )

Continue reading "CIRM training grants approved, but awards uncertain in financial climate" »